- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04712357
Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19 (ARTAN-C19)
January 14, 2021 updated by: Aldo Ângelo Moreira Lima, Universidade Federal do Ceará
Clinical, Control, Double-blind, Randomized Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19
Clinical, control, double-blind, randomized trial with tenofovir disoproxyl fumarate and emtricitabine for Covid-19
Study Overview
Status
Recruiting
Conditions
Detailed Description
Several therapeutic agents have been evaluated for the treatment of Covid-19, and only one using an antiviral drug called remdesivir administered intravenously has shown efficacy to reduce the duration of the disease in 26.7% in critically ill patients.
This proposal has as its primary objective (a) Determine the effect of TDF and TDF + FTC on the duration of Covid-19 evaluated in the 14th.
day of follow-up at the outpatient clinic in the hospital, duration of the disease observing clinical signs and symptoms, as well as evaluating the RT-PCR viral load tests on the 1st, 7th, 14th.
and 28th.
days of the study protocol.
In addition, the proposal assesses several secondary objectives: (b) Assess the action of TDF and TDF + FTC on the immune response using the rapid ELISA test (IgM / IgG) to be performed on the 7th.
and 28th.
days of monitoring the experimental protocol; (c) Determine the effect of clinical interventions with the drugs TDF and TDF + FTC in the short and medium term on the viral load of SARS-CoV-2; and (d) Assess the effect of TDF and TDF + FTC on inflammation biomarkers cytokines and chemokines (IL-6, MCP-3, D-dimer, IL1-RA, IL-10, GCSF, TNF-α, MCP-1 , IL-2R, MIP-1 alpha, IP-10, IL-8, NT-proBNP, Troponin I, CRP and procalcitonin) in the blood of patients collected in the 1st, 14th.
and 28th.
study days.
The study will be a prospective, double-blind, placebo control and randomized clinical trial of a total of 219 patients with mild to moderate disease, aged 18 years or over, with clinical signs and symptoms of Covid-19 and certified after the RT-PCR test for the detection of SARS-CoV-2 viral load.
The study will be carried out at the outpatient clinic of Hospital São José, Fortaleza, CE.
The random groups will be: (1) Group - Placebo control (Vitamin C - 500mg / day, for 10 days); (2) Group - tenofovir disoproxyl fumarate (TDF; 300 mg / day, for 10 days); and (3) Group - TDF + emtricitabine (FTC; 200 mg / day, for 10 days).
The study aims to evaluate the efficacy of tenofovir alone or combined with emtricitabine in the duration of mild to moderate Covid-19 cases.
The study will also assess the effect of drugs on viral load and immune-inflammatory response.
In this sense, the study has the perspective of minimizing the evolution of the disease to severe cases, thus relieving the collapse of the health system and minimizing the social, economic and health disorders of the pandemic by SARS-CoV-2.
Study Type
Interventional
Enrollment (Anticipated)
219
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Aldo AM Lima, Ph.D.
- Phone Number: 5585987042833
- Email: alima@ufc.br
Study Contact Backup
- Name: Alexandre H Binda, Ph.D.
- Phone Number: 5585987565695
- Email: ahavt@ufc.br
Study Locations
-
-
Ceará
-
Fortaleza, Ceará, Brazil, 60430270
- Recruiting
- Núcleo de Biomedicina - NUBIMED
-
Contact:
- Aldo A M Lima, PI
- Phone Number: +5585987042833
- Email: alima@ufc.br
-
Contact:
- Alexandre Havt Bindá, Co-PI
- Phone Number: +5585987565695
- Email: ahavt@ufc.br
-
Principal Investigator:
- Aldo A M Lima, PI
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient is > 18 years old
- Patient diagnosed with COVID-19
Exclusion Criteria:
- Patient is already receiving some of the study drugs
- There is a hospitalization plan in the next 24h
- Some study treatment is contraindicated
- Patient has HIV infection
- Patient has VHB infection
- Patient lives in another city or state
- Female patient, pregnant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo (Vitamin C)
Control placebo (Vitamin C - 500mg / day, for 10 days)
|
Vitamin C 500 MG per day for 10 days
|
Active Comparator: Tenofovir disoproxyl fumarate (TDF)
Tenofovir disoproxyl fumarate (TDF; 300 mg / day, for 10 days)
|
Tenofovir disoproxyl fumarate 300 MG per day for 10 days
|
Active Comparator: TDF + FTC
Tenofovir disoproxyl fumarate (TDF; 300 mg / day, for 10 days) plus emtricitabine (FTC; 200 mg / day, for 10 days)
|
Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG per day for 10 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The time to recovery, defined at day 7 days follow up after enrollment, on which a patient met the criteria for category 1, 2, or 3 on the eight-category ordinal scale.
Time Frame: Day 7 follow up after enrollment.
|
The categories are as follows: 1 - No signals and symptoms; 2 - One signal or symptom; 3 - Two signals or symptoms; 4 - Three or more signals or symptoms; 5 - Hospitalized, no active medical problems; 6 - Hospitalized, not on oxygen; 7 - Hospitalized, on oxygen; and 8 - Hospitalized, on high flow oxygen.
|
Day 7 follow up after enrollment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SARS-CoV-2 RNA viral load measurements change.
Time Frame: Change between Day 1 and Day 7 follow up after enrollment.
|
Molecular diagnostic analyzes will be done by Real-Time PCR (qPCR) based on official guidelines determined by the American CDC (CDC-006-00019, Revision: 03; https://www.fda.gov/media/134922/download).
The nasopharyngeal swab samples collected (Covid-19 test) will proceed to the nucleic acid isolation (NuAc).
All qPCR reactions will be by uniplex diagnosis.
Results will be reported in copies of RNA / mL.
|
Change between Day 1 and Day 7 follow up after enrollment.
|
Proportion of patients with qualitative serum IgM / IgG.
Time Frame: Proportion of positive patients at Day 28 for IgM / IgG (N; %).
|
The IgM / IgG immune response to SARS-CoV-2 will be qualitative measure using rapid diagnostic test provide by Eco Diagnóstica (Nova Lima, MG, Brazil).
|
Proportion of positive patients at Day 28 for IgM / IgG (N; %).
|
Biomarkers (IL-6, MCP-3, D-dimer, IL1-RA, IL-10, GCSF, TNF-α, MCP-1, IL-2R, MIP-1 alpha, IP-10, IL-8, NT-proBNP, Troponin I, CRP and procalcitonin) measurements change.
Time Frame: Change between Day 1 and Day 14 follow up after enrollment.
|
We will use the Luminex XMAP Technology (MAGPIX® System, Merck Co., Kenilworth, NJ) which includes the simultaneous analysis, in the same plasma sample (volume of 25 uL), of a panel of protein markers of pro and anti-inflammatory activity (IL-6, MCP-3, D-dimer, IL1-RA, IL-10, GCSF, TNF-α, MCP-1, IL-2R, MIP-1 alpha, IP-10, IL-8, NT-proBNP, Troponin I).
Specific antibodies covalently linked to the carboxylated microspheres containing different specific fluorochromes will be used.
Standard curves will be constructed for each protein and then their quantification.
Results will be reported in pg / mL.
|
Change between Day 1 and Day 14 follow up after enrollment.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 9, 2020
Primary Completion (Anticipated)
January 1, 2022
Study Completion (Anticipated)
January 1, 2023
Study Registration Dates
First Submitted
January 7, 2021
First Submitted That Met QC Criteria
January 14, 2021
First Posted (Actual)
January 15, 2021
Study Record Updates
Last Update Posted (Actual)
January 15, 2021
Last Update Submitted That Met QC Criteria
January 14, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protective Agents
- Micronutrients
- Vitamins
- Antioxidants
- Tenofovir
- Emtricitabine
- Ascorbic Acid
Other Study ID Numbers
- CAAE: 34182620.0.0000.5045
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Vitamin C 500 MG Oral Tablet
-
Rajavithi HospitalRecruitingPregnancy Anemia | Vitamin C AnemiaThailand
-
Galapagos NVCompleted
-
Helwan UniversityActive, not recruitingPost Operative Atrial FibrillationEgypt
-
Seoul National University HospitalUnknownH1N1 InfluenzaKorea, Republic of
-
Beni-Suef UniversityCompleted
-
Instituto Nacional de Perinatologia Isidro Espinosa...Active, not recruitingInsulin Resistance | PostmenopausalMexico
-
Cara Therapeutics, Inc.CompletedChronic Kidney Diseases | PruritusUnited States
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI); American Lung AssociationCompleted
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruiting